Baltijos biotechnologijos - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 4,408 | 2,817 | - | 23,858 | - | 51,375 | 366,736 | 520,129 |
| Profit before tax | -197,463 | -116,403 | -63,734 | -50,237 | -48,549 | -103,143 | -143,171 | -284,623 |
| Net profit | -197,463 | -116,403 | -63,734 | -50,237 | -48,549 | -103,143 | -143,171 | -284,623 |
| Equity | -337,539 | -453,942 | -517,676 | -71,393 | -119,942 | -223,085 | -366,256 | -650,879 |
| Liabilities | 420,564 | 513,532 | 544,446 | 315,778 | 1,326,382 | 2,389,304 | 3,268,584 | 3,298,161 |
| Non-current assets | 50,729 | 27,456 | 24,259 | 0 | 826,000 | 1,289,850 | 1,885,722 | 1,839,885 |
| Current assets | 31,817 | 32,074 | 2,358 | 244,289 | 380,282 | 876,080 | 1,016,348 | 807,159 |
| Total assets | 82,546 | 59,530 | 26,617 | 244,289 | 1,206,282 | 2,165,930 | 2,902,070 | 2,647,044 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | - | 5,183 | 113,745 |
| Social insurance contributions | - | - | - | - | - | 4,007 | 15,710 | 16,638 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -94.9% | -36.1% | - | - | - | - | +613.8% | +41.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -239.2% | -195.5% | -239.4% | -20.6% | -4.0% | -4.8% | -4.9% | -10.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | - | - | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -4479.7% | -4132.2% | - | -210.6% | - | -200.8% | -39.0% | -54.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -4479.7% | -4132.2% | - | -210.6% | - | -200.8% | -39.0% | -54.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | - | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 1,469 | 1,166 | - | 14,315 | - | 15,413 | 88,016 | 130,032 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Baltijos biotechnologijos - Social security debts
The company had no debts to Sodra
Baltijos biotechnologijos - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Baltijos biotechnologijos, UAB (company code 303110825) is a Private Limited Liability Company engaged in development of building projects. In 2025, revenue increased to €520.1K, up 41.8% year on year and 912.4% over two years, showing a strong expansion from the €51.4K recorded in 2023 and €366.7K in 2024. Despite the higher turnover, profitability remained negative and weakened further: net loss widened to €284.6K in 2025 from €143.2K in 2024 and €103.1K in 2023, while the net margin fell to -54.7%. The balance sheet remained strained, with total assets of €2.65M, liabilities of €3.30M and negative equity of €650.9K at the end of 2025. Long-term assets were €1.84M and short-term assets €807.2K. Asset turnover was 0.20x, indicating limited revenue generation relative to the asset base. Revenue per employee stood at €130.0K, while profit per employee was negative at €71.2K. The negative equity position means leverage-related ratios should be read cautiously.